Simplicity Solutions LLC Acquires New Shares in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Simplicity Solutions LLC acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 12,584 shares of the biopharmaceutical company’s stock, valued at approximately $141,000.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Theravance Biopharma by 10.3% in the 1st quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock valued at $66,421,000 after buying an additional 648,124 shares in the last quarter. BlackRock Inc. boosted its stake in Theravance Biopharma by 1.7% in the 3rd quarter. BlackRock Inc. now owns 5,107,527 shares of the biopharmaceutical company’s stock worth $51,789,000 after purchasing an additional 84,787 shares during the period. Newtyn Management LLC boosted its stake in Theravance Biopharma by 12.3% in the 3rd quarter. Newtyn Management LLC now owns 1,841,560 shares of the biopharmaceutical company’s stock worth $15,893,000 after purchasing an additional 201,104 shares during the period. Bank of America Corp DE boosted its stake in Theravance Biopharma by 102.4% in the 1st quarter. Bank of America Corp DE now owns 1,775,966 shares of the biopharmaceutical company’s stock worth $19,269,000 after purchasing an additional 898,691 shares during the period. Finally, State Street Corp boosted its stake in Theravance Biopharma by 13.3% in the 1st quarter. State Street Corp now owns 1,541,533 shares of the biopharmaceutical company’s stock worth $14,737,000 after purchasing an additional 181,331 shares during the period. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

Theravance Biopharma stock opened at $9.34 on Monday. The firm has a 50-day moving average of $9.01 and a 200-day moving average of $9.68. Theravance Biopharma, Inc. has a one year low of $8.21 and a one year high of $11.98.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. The business had revenue of $17.57 million for the quarter, compared to analyst estimates of $17.49 million. Analysts forecast that Theravance Biopharma, Inc. will post -0.84 EPS for the current year.

Analysts Set New Price Targets

TBPH has been the subject of a number of research analyst reports. Evercore ISI lowered shares of Theravance Biopharma from an “outperform” rating to an “inline” rating in a research note on Monday, January 8th. BTIG Research initiated coverage on shares of Theravance Biopharma in a research note on Friday, April 12th. They issued a “buy” rating and a $21.00 target price for the company.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.